利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

101 条记录 (耗时 0.02 秒)

    Preparation of alkyl cyanoacetates
    1.
    发明授权
    Preparation of alkyl cyanoacetates 失效
    氰基乙酸烷基酯的制备

    公开(公告)号：US4322369A

    公开(公告)日：1982-03-30

    申请号：US216363

    申请日：1980-12-15

    申请人： Michel Desbois ,  Gerard Soula

    发明人： Michel Desbois ,  Gerard Soula

    IPC分类号： C07C255/19 ,  C07C67/00 ,  C07C253/00 ,  C07C120/04

    CPC分类号： C07C255/00 ,  C07C253/14

    摘要： The alkyl cyanoacetates are prepared by reacting an alkyl chloracetate with an excess of an alkali metal cyanide, in an inert solvent and in the presence of at least one tertiary amine sequestering agent having the formula:N--CHR.sub.1 --CHR.sub.2 --O--CHR.sub.3 --CHR.sub.4 --O.sub.n R.sub.5 ].sub.3 (I).

    摘要翻译： 氰基乙酸烷基酯通过使氯代乙酸烷基酯与过量的碱金属氰化物在惰性溶剂中并在至少一种具有下式的叔胺螯合剂的存在下反应制备：N-CHR1-CHR2-O-CHR3-CHR4 -OnR5] 3（I）。

    Complex consisted of a polysaccharide and an HBP
    4.
    发明申请
    Complex consisted of a polysaccharide and an HBP 有权
    复合物由多糖和HBP组成

    公开(公告)号：US20100184965A1

    公开(公告)日：2010-07-22

    申请号：US12585886

    申请日：2009-09-28

    申请人： Olivier Soula ,  Remi Soula ,  Martin Gaudier ,  Gerard Soula

    发明人： Olivier Soula ,  Remi Soula ,  Martin Gaudier ,  Gerard Soula

    IPC分类号： A61K47/48 ,  C08B37/04 ,  C08B15/06 ,  C08B37/00

    CPC分类号： A61K9/0019 ,  A61K9/19 ,  A61K38/1825 ,  A61K38/185 ,  A61K38/1866 ,  A61K38/27 ,  A61K38/29 ,  A61K47/42 ,  A61K47/61

    摘要： The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs.

    摘要翻译： 本发明涉及由多糖和HBP组成的复合物，所述多糖由（1,6）和/或（1,4）和/或（1,3）和/或（1,2）的糖苷键组成 ）类型并用至少一种可成盐或盐化的色氨酸衍生物官能化。 本发明还涉及包含根据本发明的复合物和由（1,6）和/或（1,4）和/或（1,3）和/或（1,3）的糖苷键组成的多糖和/ 或（1,2）型，并用至少一种可成盐或盐化的色氨酸衍生物官能化，用于制备稳定HBP的药物制剂。

    Angiogenic composition
    6.
    发明申请
    Angiogenic composition 审中-公开
    血管生成成分

    公开(公告)号：US20080293635A1

    公开(公告)日：2008-11-27

    申请号：US12078443

    申请日：2008-03-31

    申请人： Olivier Soula ,  Gerard Soula ,  Remi Soula ,  Rosy Eloy

    发明人： Olivier Soula ,  Gerard Soula ,  Remi Soula ,  Rosy Eloy

    IPC分类号： A61K38/16 ,  A61P9/00

    CPC分类号： A61K9/0014 ,  A61K38/1858 ,  A61K47/61

    摘要： The present invention relates to a amphiphilic polymer in the preparation of a therapeutic composition for promoting angiogenesis at its site of administration, comprising a complex between a polymer and a PDGF, wherein the polymer is amphiphilic.In an embodiment, the PDGF is selected from the group of the PDGFs (platelet-derived growth factors) and the amphiphilic polymer is selected from the group: The invention relates also to the therapeutic composition is in the form of a gel, a cream, a solution, a spray, a paste or a patch or a dressing.

    摘要翻译： 本发明涉及制备用于在其施用部位促进血管发生的治疗组合物的两亲性聚合物，其包含聚合物和PDGF之间的复合物，其中所述聚合物是两亲性的。 在一个实施方案中，PDGF选自PDGF（血小板衍生生长因子）组，两亲性聚合物选自：本发明还涉及治疗组合物，其形式为凝胶，霜剂， 溶液，喷雾剂，糊剂或贴剂或敷料。

    Telechelic Homopolyamino Acids Functionalized with Hydrophobic Groups, and Their Applications, Especially Therapeutic Applications
    7.
    发明申请
    Telechelic Homopolyamino Acids Functionalized with Hydrophobic Groups, and Their Applications, Especially Therapeutic Applications 失效
    用疏水基团功能化的远端肝氨基酸及其应用，特别是治疗应用

    公开(公告)号：US20070265192A1

    公开(公告)日：2007-11-15

    申请号：US10574475

    申请日：2004-09-28

    申请人： Rémi Soula ,  You-Ping Chan ,  Gerard Soula ,  Olivier Breyne

    发明人： Rémi Soula ,  You-Ping Chan ,  Gerard Soula ,  Olivier Breyne

    IPC分类号： A61K47/30 ,  A61K38/28 ,  A61P3/10 ,  C07C229/12

    CPC分类号： A61K8/88 ,  A61K9/1075 ,  A61K9/5146 ,  A61K47/34 ,  A61K47/645 ,  A61Q19/00 ,  C08G69/10 ,  C08G73/028 ,  C08L79/02

    摘要： The invention relates to novel materials based on biodegradable homopolyamino acids and which can be used for the vectorization of (an) active ingredient(s) (AI). The invention also relates to novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on said homopolyamino acids. The aim of the invention is to produce a novel polymer raw material which can be used for the vectorization of AI and which meets all specifications in an optimum manner: biocompatibility, biodegradability, the ability to become easily associated with a large number of active ingredients or to solubilize them and to release said ingredients in vivo. According to the present invention, which primarily relates to linear homopolyamino acids having aspartic or glutamic units and whose extremities include hydrophobic groups having 8-30 carbon atoms. Said homopolymers are amphiphilic and anionic and can easily be transformed at low cost into particles for the vectorization of active ingredients. Said particles can form stable aqueous colloidal suspensions.

    摘要翻译： 本发明涉及基于可生物降解的均聚氨基酸的新型材料，其可用于（a）活性成分（AI）的向量化。 本发明还涉及基于所述均聚氨基酸的新型药物，化妆品，饮食或植物检疫组合物。 本发明的目的是生产一种新颖的聚合物原料，其可用于AI的载体化并且以最佳方式满足所有规格：生物相容性，生物降解性，与许多活性成分容易相关的能力或 以溶解它们并在体内释放所述成分。 根据本发明，其主要涉及具有天冬氨酸或谷氨酸单元的线性均聚氨基酸，其末端包括具有8-30个碳原子的疏水基团。 所述均聚物是两亲性的和阴离子的，并且可以容易地以低成本转化成用于活性成分载体化的颗粒。 所述颗粒可以形成稳定的水性胶体悬浮液。

    Oral ribavirin pharmaceutical compositions
    8.
    发明申请
    Oral ribavirin pharmaceutical compositions 审中-公开

    公开(公告)号：US20070166378A1

    公开(公告)日：2007-07-19

    申请号：US11449675

    申请日：2006-06-09

    申请人： Florence Guimberteau ,  Catherine Castan ,  Remi Meyrueix ,  Gerard Soula

    发明人： Florence Guimberteau ,  Catherine Castan ,  Remi Meyrueix ,  Gerard Soula

    IPC分类号： A61K31/7056 ,  A61K9/22

    CPC分类号： A61K9/5026 ,  A61K9/2077 ,  A61K9/48 ,  A61K9/5042 ,  A61K31/7056

    摘要： The invention relates to oral pharmaceutical compositions for the prevention and/or the treatment of viral diseases. This invention also addresses methods of prevention and/or treatment of these viral diseases, using these oral compositions. One of the main problems considered in the present invention is to enhance the efficiency of anti-viral treatments, especially against Hepatitis C virus by means of ribavirin, for example in combination with interferon. The oral ribavirin antiviral composition according to the invention increases the bio-absorption time of ribavirin, and thus improves the treatment of patients. Said composition comprises at least one modified release form of ribavirin, the bio-absorption time BAT of which is greater than the bio-absorption time BAT* of a reference* immediate release form of ribavirin administered at the same dose; BAT being preferably comprised between 2 and 15 h and more preferably between 4 and 12 h. Said composition is a reservoir type form or a matrix type form. Said composition is a gastric retentive system or a multiparticulate form.